Dolutegravir: 8 agencies, 2014–2023
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 9.2 years, from 12 May 2014 at SMC (Scotland) to 5 Jul 2023 at CONITEC (Brazil).
HAS (France) changed its position: recommended on 28 May 2014, not recommended by 7 Jul 2021.
No assessment is on file from TLV (Sweden) and CIPM (Spain), each among the eight highest-volume agencies here.
6 distinct indication wordings are recorded for dolutegravir by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 20 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess dolutegravir, on 12 May 2014; AWMSG (Wales) did not open a file until 19 Oct 2017 — a wide spread of 3.4 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 8 years in total.
7 of the 8 agencies here assessed dolutegravir more than once, CONITEC (Brazil) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for dolutegravir.
The full ledger for dolutegravir reads 13 recommended, 2 no benefit, 2 not recommended and 2 restricted, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 5 Jul 2023 | Tratamento da infecção pelo HIV em crianças. | incorporated into SUS | source |
| AWMSG (Wales) | 30 Sep 2021 | In combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) inf… | recommended (limited) | source |
| G-BA (Germany) | 15 Jul 2021 | Tivicay — benefit assessment §35a | added benefit: not proven | source |
| HAS (France) | 7 Jul 2021 | Listing (Transparency Committee) | SMR insufficient · ASMR II | source |
| PBAC (Australia) | 2019 | Human immunodeficiency virus (HIV) | infection | The PBAC deferred making a recommendation for a fixed-dose combination of dolutegravir wit… | source |
15 further decisions for dolutegravir, across 8 agencies, are not shown here. They link to 10 further source documents.
Related molecules
- raltegravir — divergent outcome (recommended vs restricted) on a shared indication
- bictegravir / emtricitabine / tenofovir alafenamide — divergent outcome (recommended vs restricted) on a shared indication
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
Coverage: 20 decisions for dolutegravir from 8 agencies, 2014 to 2023. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.